Briacell Therapeutics Corp BCTX

$3.30 -0.09 (-2.65%)

Valuation

Market cap
29,603,000
Revenue TTM
$0
Net income TTM
$-34,900,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
28,900
Avg volume
97,506
Day's range
$3.29 – $3.44
Shares out
8,732,000
Stochastic %K
37%
Beta
1.26
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604-921-1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

BHWinehouse Nov 16, 12:37 PM
$INCY $BCTX I believe there is a good possibility this moves beyond a simple drug-supply agreement. Time will tell if I'm right or not.
1 replies
CoffeeRocks Nov 16, 12:15 PM
$ABCL $BCTX $IOVA $LPCN $SLS BCTX LPCN inching up a bit
0 replies
Merlintrader Nov 14, 11:08 PM
$BCTX Nov 6: BriaCell and BriaPro presented preclinical findings across four SITC posters, including Bria-OTS+ immune activation and BP-80 tolerability in primates. These are preclinical findings and do not establish efficacy in patients. Not investment advice. More context and primary sources in our $BCTX stock hub: https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 replies
CoffeeRocks Nov 13, 8:41 PM
$LPCN $SLS $IOVA $ABCL $BCTX LOCN catching a BiD????? 1.5$S to ?????
0 replies
PensiveInvestor Nov 13, 3:22 PM
$BCTX Candel is the winner
1 replies
BHWinehouse Nov 13, 12:31 PM
$BCTX So, did we win? https://citeline.com/awards/citelineawards/
1 replies
Biotechlineup Nov 13, 12:16 AM
$BCTX valuation based on an independent study.
0 replies
Biotechlineup Nov 13, 12:14 AM
$BCTX bottom line Bull Case, Clean DSMB safety/futility reviews, a strong hint that slower event accrual reflects patients living longer than expected, cash runway through the interim readout, and active behind-the-scenes discussions with potential partners.
0 replies